Aesica

Aesica - Active Pharmaceutical Ingredients Supplier

Established since the late 1970s in Cramlington in North-Eastern England, Aesica is a leading supplier of active pharmaceutical ingredients, with customers in every continent, ranging from small start up companies to global giants within the pharmaceutical industry. Since the opening of the facility the site has seen significant investment with the goal of providing manufacturing excellence and first class customer relationships. Aesica's products include Paroxetine Hydrochloride Anhydrous, Flurbiprofen, Sodium Flurbiprofen.

EXTENSIVE CHEMICAL PROCESSING

Two computer controlled multi-product plants with extensive chemical processing capability. All Aesica products are manufactured to cGMP standards. On each FDA audit we have demonstrated that the standards of Aesica products are amongst the highest in the world. Aesica are also cGMP certified by the MHRA, the UK's Pharmaceutical Regulatory Agency and in addition Aesica is also certified to ISO 9000-2000, the international standard that promotes the use of a process approach to meet and exceed customer requirements.

KILO LAB - DRYING FACILITIES AND HYDROGENATION CAPABILITY

In 2003, Aesica commissioned a new kilo laboratory with 20ft glassware, large-scale distillation, drying facilities and hydrogenation capability. The facility can be used for scale-up studies and to produce material for early stage clinical trials. It is also currently used as the manufacturing site for one of our products supplied for an ophthalmic application.

CHEMICAL DEVELOPMENT

Aesica's new technical centre was opened in 2003 and provides up to date facilities for our team of chemists and chemical engineers.

FLURBIPROFEN, SODIUM FLURBIPROFEN, R-FLURBIPROFEN, S-FLURBIPROFEN

Aesica is the world's largest manufacturer of flurbiprofen products. The site was initially developed to manufacture flurbiprofen in a purpose built facility, and after a series of plant expansions and adaptations this is now a multi-product facility. Aesica has a US DMF and a European DMF and sells material into every continent.

PAROXETINE ANHYDROUS HCI

Aesica has its own unique process for manufacturing Anhydrous Paroxetine HCL and has patented steps in that process. We believe that it does not infringe any valid patent owned by the originator.

Currently we have a US DMF and a European DMF and are supplying leading generic customers in Europe, North America and South America.

DOTHIEPIN HCI - TRICYCLIC ANTI-DEPRESSANT

Aesica has a European DMF for dothiepin and has manufactured this well trusted tricyclic anti-depressant for many years.

Aesica Pharmaceuticals Ltd
Windmill Industrial Estate
Shotton Lane
Cramlington
Northumberland, NE23 3JL
United Kingdom
Tel: +44 1670 590595
Fax: +44 1670 597360
Email: Maria.Koustareva@aesica-pharma.com
URL: www.aesica-pharma.com

Printable Version Print friendly version

Regional Offices Regional Offices


Send an Enquiry





Expand Image
Our focus now more than ever is to reflect the importance of our customers and stakeholders.
Our focus now more than ever is to reflect the importance of our customers and stakeholders.
Expand Image
Protection of the environment and safety of our employees and the community have always been an important part of our business.
Protection of the environment and safety of our employees and the community have always been an important part of our business.
Expand Image
Our state of the art quality control testing facilities ensure that our customers always receive a high quality product.
Our state of the art quality control testing facilities ensure that our customers always receive a high quality product.
Expand Image
Our core technologies are a key factor in making us a first choice manufacturing supplier.
Our core technologies are a key factor in making us a first choice manufacturing supplier.
Expand Image
Our development lab has state-of-the-art technology and the capacity to manufacture development compounds for use in Phase I to III clinical trials.
Our development lab has state-of-the-art technology and the capacity to manufacture development compounds for use in Phase I to III clinical trials.
RELATED LINKS

client logon
Home
Industry Projects
Company A-Z
White Papers
Jobs & Careers
Press Releases
Advertise With Us
Events & Exhibitions
Newsletter
New On This Site
About Us
Atom FeedRSS Feed
What is RSS?